TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22340437
Drug: Endovascular thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombolysis (local application of rt-plasminogen activator or urokinase, mechanical thrombosuction, or a combination of both) with heparin before and after the procedure.
Study: 22340437
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (therapeutic doses of heparin).
Study: 22342057
Drug: Intrasphincteric autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrasphincteric autologous myoblast injections followed by electrical stimulation (ES)
Study: 22351714
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of fructose in hypercaloric trials (+104 to 250 g/d, +18% to 97% of total daily energy intake)
Study: 22352764
Drug: NP101 transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP101 transdermal sumatriptan patch
Study: 22353806
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin (LD) 40 mg m(-2) plus cisplatin 60 mg m(-2) every 21 days
Study: 22354139
Drug: Basic Activities
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Activities of Daily Living (BADL)
Study: 22354206
Drug: DVD-R regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVD-R regimen (pegylated liposomal doxorubicin 4.0 mg/m(2), bortezomib 1.0 mg/m(2), dexamethasone 40 mg, lenalidomide 10 mg daily)
Study: 22357361
Drug: Congestive heart
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congestive heart failure patients receiving both beta-blockers and antagonists of the renin-angiotensin-aldosterone system (n=511)
Study: 22357361
Drug: Congestive heart
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congestive heart failure patients receiving neither renin-angiotensin-aldosterone system blockers nor beta-blockers (n=498)
Study: 22357361
Drug: Congestive heart
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Congestive heart failure patients receiving only one of the recommended classes of medications
Study: 22357572
Drug: Active-minocycline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-minocycline plus active-aspirin
Study: 22357572
Drug: Active-minocycline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active-minocycline plus placebo-aspirin
Study: 22357572
Drug: Placebo-minocycline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-minocycline plus active-aspirin
Study: 22357572
Drug: Placebo-minocycline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-minocycline plus placebo-aspirin
Study: 22357572
Drug: Minocycline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline and aspirin
Study: 22360915
Drug: Concurrent prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent prophylactic placement of inferior vena cava filter (CPIVCF)
Study: 22360944
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention and stenting with different drug-eluting coatings and platforms
Study: 22363068
Drug: Gemcitabine (675
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (675 mg/m2 i.v. over 90 minutes on days 1 and 8) in combination with docetaxel (75 mg/m2 i.v. over 1 hour on day 8) every 21 days; all patients received filgrastim or pegfilgrastim.
Study: 22367707
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with panitumumab (gemcitabine 1000 mg/m², oxaliplatin 60 mg/m², panitumumab 6 mg/kg i.v. every 2 weeks followed by capecitabine 1000 mg/m² for 7 days)
Study: 22371427
Drug: Neratinib 240
Normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neratinib 240 mg once daily (maximum-tolerated dose)
Study: 22371427
Drug: Neratinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (various doses: 80, 160, 240, 320 mg)
Study: 22371427
Drug: Neratinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (various doses)
Study: 22373834
Drug: Tocilizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (10 mg/kg intravenously on Day 8)
Study: 22373834
Drug: Methotrexate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (10 - 25 mg orally on Days 1, 8, 15, 22, 29, 36, and 43)
Study: 22373835
Drug: Sertraline 5
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 5 mg/d
Study: 22373835
Drug: Sertraline 25
Normalized name: sertraline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 25 mg/d
Study: 22373906
Drug: ANGELS of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANGELS of AF intervention (specific reports on stroke risk factors and antithrombotic therapy)
Study: 22377126
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy (fluorouracil, epirubicin, cyclophosphamide, and bevacizumab for cycles 1-4; docetaxel, bevacizumab, and trastuzumab for cycles 5-8)
Study: 22377126
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy with bevacizumab, trastuzumab, and chemotherapy
Study: 22378328
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement, education, promotion of existing clinical services, and social support (24-week intervention)
Study: 22381092
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.5% ropivacaine bilaterally into the TAP
Study: 22381365
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with 500 mg vitamin C, 400 IU vitamin E, 15 mg β-carotene, 80 mg zinc oxide, and 2 mg cupric oxide per day for 5 days.
Study: 22382879
Drug: linifanib 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: linifanib 0.10 mg/kg
Study: 22382879
Drug: linifanib 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: linifanib 0.25 mg/kg
Study: 22386040
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home QT interval monitoring using HeartView™ ECG recorder for 6 months
Study: 22386040
Drug: Daily home
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily home QT interval monitoring
Study: 22388706
Drug: Sufentanil bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil bolus, starting at 0.15 μg/kg
Study: 22393174
Drug: Bovine insulin-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine insulin-free cow's milk formula (CMF)
Study: 22393174
Drug: Whey-based FINDIA
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey-based FINDIA formula (essentially free of bovine insulin)
Study: 22394984
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at 1.3 mg/m(2) for normal function; 0.5 mg/m(2) for severe impairment; 0.7 mg/m(2) for moderate impairment; 1.0 mg/m(2) for mild impairment.
Study: 22394984
Drug: Bortezomib at
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib at 0.7 mg/m(2) for moderate impairment; 0.5 mg/m(2) for severe impairment.
Study: 22394992
Drug: MenC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC vaccine (control)
Study: 22396517
Drug: Bevacizumab, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab, 5 mg per kg, every 14 days for a total of 6 injections.
Study: 22396585
Drug: Amlodipine or
Normalized name: amlodipine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine or Lisinopril with incident diabetes
Study: 22397748
Drug: Repeated ultrasound-guided
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ultrasound-guided transvaginal ovarian interstitial laser treatment
Study: 22398655
Drug: Edoxaban with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban with 50% dose reductions for patients with moderate renal impairment or receiving concomitant strong P-glycoprotein (P-gp) inhibitors
Study: 22399525
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL mangosteen juice with a high-fat breakfast
Study: 22401488
Drug: Antidepressants (added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (added to mood stabilizers and/or atypical antipsychotics)
Study: 22402037
Drug: PADRE-CMV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PADRE-CMV vaccine with PF03512676 adjuvant
Study: 22402037
Drug: Tetanus-CMV vaccine
Normalized name: tetanus toxoid vaccine, inactivated
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus-CMV vaccine with PF03512676 adjuvant
Study: 22402037
Drug: CMV peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV peptide vaccines without PF03512676 adjuvant
Study: 22406240
Drug: Subgroup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup of MMT patients with positive urine morphine test
Study: 22406240
Drug: Subgroup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgroup of MMT patients not using benzodiazepine hypnotics
Study: 22411933
Drug: high-exposure arm
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-exposure arm (guideline-based therapy supplemented with antibiotic escalation)
Study: 22411933
Drug: standard-exposure arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard-exposure arm (guideline-based therapy)
Study: 22411933
Drug: eGFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <60 ml/min/1.73 m(2) at entry
Study: 22411933
Drug: eGFR <60
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <60 ml/min/1.73 m(2) at last day of follow-up
Study: 22415795
Drug: Saracatinib 50
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 50 mg
Study: 22415795
Drug: Saracatinib 125
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 125 mg
Study: 22415795
Drug: Saracatinib 175
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 175 mg
Study: 22415795
Drug: Saracatinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib (all doses)
Study: 22415951
Drug: Intraspinal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraspinal infusion of autologous bone marrow mononuclear cells (BMNCs)
Study: 22416063
Drug: CBT-1® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-1® (500 mg/m2 for 7 days)
Study: 22416063
Drug: CBT-1® (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-1® (500 mg/m2 for 7 days) + paclitaxel (135 mg/m2 on day 6)
Study: 22416063
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2 on day 6)
Study: 22419719
Drug: Cancer-cachexia (CC)
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer-cachexia (CC)
Study: 22420838
Drug: Aggressive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fever treatment strategy (acetaminophen 650 mg enterally every 6 hours for temperatures ≥ 38.3 °C; external cooling for temperatures ≥ 39.5 °C)
Study: 22420838
Drug: Permissive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive fever treatment strategy (acetaminophen 650 mg every 6 hours for temperatures ≥ 40.0 °C; external cooling for temperatures ≥ 40.5 °C)
Study: 22420838
Drug: Aggressive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive fever treatment strategy
Study: 22420838
Drug: Permissive fever
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permissive fever treatment strategy
Study: 22421227
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (stents and pharmacotherapy)
Study: 22421340
Drug: Tocilizumab (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (4-8 mg/kg every 4 weeks)
Study: 22422792
Drug: Pharmaceutical thrombosis
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH)
Study: 22422826
Drug: Ruxolitinib 25
Normalized name: ruxolitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle), with dose escalation to 50 mg twice daily permitted for patients showing benefit.
Study: 22423615
Drug: Intensity-modulated and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated and image-guided radiotherapy (IMRT-IGRT) by helical tomotherapy, delivering a dose of 50 Gy in fractions of 5 Gy.
Study: 22424004
Drug: Collaborative quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative quality initiatives including radiation dose reduction and appropriate CCTA use
Study: 22424178
Drug: Salbutamol (short-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (short-acting bronchodilator)
Study: 22425095
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg with continuous daily dosing
Study: 22426369
Drug: AS03-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H1N1 influenza vaccine (3.75µg HA)
Study: 22429873
Drug: Inpatient weight-loss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient weight-loss program for children and adolescents (4 to 6 weeks duration) focusing on diet, physical activity, and behavior therapy.
Study: 22431570
Drug: Obinutuzumab (GA101)
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab (GA101) administered in a dose-escalating fashion (3 per cohort, range 50/100-1200/2000 mg) for 8 × 21-day cycles
Study: 22432117
Drug: Dopamine type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine type 2 receptor (D2R) availability measured using positron emission tomography and [(18)F]fallypride
Study: 22432687
Drug: Cognitex supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitex supplementation (3 capsules per day for 12 weeks)
Study: 22433615
Drug: Behavioral obesity
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral obesity treatment
Study: 22436661
Drug: H-1PV by
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-1PV by intratumoral injection and administration into the walls of the tumor cavity during tumor resection
Study: 22437560
Drug: Milk intake
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk intake (L/d)
Study: 22438225
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention program (exercise, behavior, and nutrition therapy) for 1 year
Study: 22438229
Drug: Alipogene tiparvovec
Normalized name: alipogene tiparvovec
DrugBank: Alipogene tiparvovec (DB13521)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Alipogene tiparvovec (AAV1-LPL(S447X)), administered at a dose of 1 × 10(12) genome copies per kilogram, intramuscularly.
Study: 22438256
Drug: Obinutuzumab induction
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab induction (200-2000 mg IV weekly for 4 weeks) followed by maintenance every 3 months for a maximum of 8 doses
Study: 28011903
Drug: Obinutuzumab maintenance
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Obinutuzumab maintenance therapy
Study: 22438987
Drug: Sublingual (SL)
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual (SL) administration of quadravalent HPV vaccine (n = 12)
Study: 22438987
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) administration of quadravalent HPV vaccine (n = 6)
Study: 22439666
Drug: Cetuximab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (single agent treatment)
Study: 22439666
Drug: Folfiri-cetuximab regimen
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Folfiri-cetuximab regimen (after initial treatment with cetuximab)
Study: 23118984
Drug: MVA-NP+M1 vaccine
Normalized name: Ceramide Np
DrugBank: Ceramide NP (DB14111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-NP+M1 vaccine
Study: 22443231
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL ropivacaine 0.75%
Study: 22443231
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL ropivacaine 0.75%
Study: 22443231
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL ropivacaine 0.75%
Study: 22443293
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release (50-250 mg bid) during a 5-week titration and 7-week maintenance period.
Study: 22443293
Drug: Tapentadol prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol prolonged release treatment for patients with neuropathic pain component.
Study: 22443802
Drug: Neoadjuvant short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant short course intensity-modulated radiation therapy (5 × 5 Gy) and intraoperative radiation therapy (15 Gy)
Study: 22445005
Drug: Concurrent temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concurrent temozolomide with protocol radiotherapeutic treatment.
Study: 22446154
Drug: Four-month daily
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-month daily pelvic floor muscle (PFM) strengthening exercise program at home
Study: 22447809
Drug: Sildenafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (40 or 80 mg)
Study: 22448814
Drug: BCX1777 (forodesine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX1777 (forodesine) 100 mg/day
Study: 22448814
Drug: BCX1777 (forodesine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX1777 (forodesine) 200 mg/day
Study: 22448814
Drug: BCX1777 (forodesine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX1777 (forodesine) 300 mg/day
Study: 22448921
Drug: Combotox (low-dose)
Normalized name: ibuprofen / oxycodone hydrochloride Oral Tablet [Combunox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combotox (low-dose) + Cytarabine (Ara-C)
Study: 22448921
Drug: Combotox (high-dose)
Normalized name: ibuprofen / oxycodone hydrochloride Oral Tablet [Combunox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combotox (high-dose) + Cytarabine (Ara-C)
Study: 22448921
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of Ara-C and Combotox
Study: 22448921
Drug: Concurrent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent administration of Ara-C and Combotox
Study: 22450529
Drug: Ultrasound-guided TAP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided TAP blocks with bilateral injections of 20 ml ropivacaine 0.5% w/v (total dose 200 mg)
Study: 22451423
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bendamustine (75 mg/m² on days 1 and 2), lenalidomide (10 mg on days 1-21), and dexamethasone (40 mg weekly) in a 28-day cycle
Study: 22451423
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bendamustine, lenalidomide, and dexamethasone
Study: 22452895
Drug: Afatinib 50
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib 50 mg daily
Study: 22452895
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg daily
Study: 22454801
Drug: Aripiprazole (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (15-30 mg/d)
Study: 22454801
Drug: Lithium (900-1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (900-1500 mg/d)
Study: 22455454
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 150 mg eq (234 mg) administered via deltoid injection, with subsequent once-monthly injections of the same dose.
Study: 22456429
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg intravenous, four doses every 3 weeks, then every 12 weeks for clinically stable patients)
Study: 22456429
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg intravenous)
Study: 22456661
Drug: Multiple-criteria model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-criteria model (≥ 2 of 3 abnormal ferritin < 12 μg/L, soluble transferrin receptor (TfR) > 8.3 mg/L, zinc protoporphyrin (ZP) > 80 μmol/mol)
Study: 22456662
Drug: Zinc depletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc depletion (10 d, 0.3 mg Zn/d)
Study: 22456662
Drug: Zinc repletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc repletion (7 d, 29.5 mg Zn/d)
Study: 22456662
Drug: Zinc acclimation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc acclimation (7 d, 10.4 mg Zn/d)
Study: 22461458
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies based on identified mutations and alterations in protein expression
Study: 22465364
Drug: Subconjunctival sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival sirolimus (30 μL, 1320 μg)
Study: 22466348
Drug: Mifepristone (300-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (300-1200 mg daily)